Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05050929 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RAPid SimPLE Targeted Radiation Treatment for Brain Metastases

Study acronym: RAPPLE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Eligibility criteria expanded, about 25 words · Site details revised at 6 of 6 sites · Publications: details revised at 1 of 1 entry Show 3 more changesShow less
    • Eligibility criteria expanded, about 25 words
    • Site details revised at 6 of 6 sites
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Jun 30, 2026 to Dec 30, 2026 Completion date: Jun 30, 2027 to Dec 30, 2027 · Eligibility criteria shortened, about 58 words · Site details revised at 2 of 6 sitesv4 Show 3 more changesShow less
    • Completion date: Jun 30, 2027 to Dec 30, 2027
    • Eligibility criteria shortened, about 58 words
    • Site details revised at 2 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 1 to 6v3
  4. Phase: Phase 2/3 to Phase 2 Trial status: Not Yet Recruiting to Recruiting · Primary completion date: Dec 31, 2025 to Jun 30, 2026 · Start date changed from estimate of Nov 1, 2021 to Jul 1, 2022 · 2 morev2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Dec 31, 2025 to Jun 30, 2026
    • Start date changed from estimate of Nov 1, 2021 to Jul 1, 2022
    • Completion date: Jul 1, 2026 to Jun 30, 2027
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
Trial Details
NCT Number NCT05050929
Lead Sponsor British Columbia Cancer Agency
Collaborators: Varian Medical Systems
Conditions Brain Metastases, Adult
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov